Xynomic Extends Phase III Abexinostat Trial to China and Europe

Published on: March 18, 2019
Author: Amy Liu

Xynomic, a US-Shanghai oncology pharma, announced that China, Spain and Poland authorities have approved Phase III trials of Xynomic’s abexinostat, in combination with pazopanib, in patients with renal cell carcinoma (RCC). Abexinostat is a novel HDAC inhibitor. Xynomic has already started the same trial in the US and South Korea. Xynomic in-licensed the drug in 2017 (see story), but did not disclose details of the transaction. The molecule was developed by Pharmacyclics, which was acquired by AbbVie in 2015.

Source: China Biotoday

Biotechnology Genomics Healthcare Services Life Science Medical Device Pharmaceutical